Norovirus VLP vaccine: Phase I data

Data from the double-blind, U.S. Phase I LV01-102 trial in 61 healthy volunteers ages 18-49 showed that 50 and 100 µg doses of intranasal Norovirus VLP vaccine produced significantly higher seroconver...